



Mr Kyle Dunton
Director, Market Access and HEOR
Daiichi Sankyo

Ms Anna Arent
Head of Oncology
Astra Zeneca UK

Wednesday 29th April 2026

Dear Kyle and Anna,

I am writing to you on behalf of the All-Party Parliamentary Group on Breast Cancer, to urge you to submit a new commercial offer to NICE for your drug Enhertu for HER2-low secondary breast cancer, to allow it to be made available for patients on the NHS.

As you know, patient led organisations like Breast Cancer Now, METUPUK and Make 2nds Count have long been calling for you, the government and NICE to work together to give metastatic (also known as secondary) breast cancer patients access to the life-extending treatments they need and deserve.

Which is why we welcome the government's recent commitment to increase the cost-effectiveness threshold for new medicines for the first time in over 20 years.

The cost effectiveness threshold used to decide if medicines can be approved for patients on the NHS in England has increased. This rise from £20,000-£30,000 to £25,000-£35,000 will give NICE the chance to approve more new treatments for patients.

The new cost-effectiveness thresholds still fall short of allowing the NHS to spend the same amount for some medicines as before the introduction of the severity modifier in 2022. However, we believe that this change should be enough for some drugs impacted by that change to now be approved and made available to patients.

This presents an incredible opportunity to break the deadlock and make Enhertu available on the NHS for people with HER2-low metastatic breast cancer who desperately need it and are still unable to access it.

We understand that commercial negotiations are complex. But for people living with metastatic breast cancer who could benefit from Enhertu, it is simple – they do not have time to wait.

Many women who have campaigned for Enhertu to be made available have since died.



This includes women who made time to meet with representatives from your companies, alongside NHS England and NICE, in parliament in May 2024 as part of the work of the previous All-Party Parliamentary Group on Breast Cancer.

With this in mind, will you please urgently confirm if you plan to submit a new commercial offer to NICE for Enhertu for HER2-low metastatic breast cancer so it can be considered under the new cost-effectiveness thresholds?

Yours sincerely,

Clive Jones MP

Member of Parliament for Wokingham